TruSight Tumor 26 takes a deeper view of variation in solid tumors including lung, colon, melanoma, gastric and ovarian. This enables clinical researchers to identify low-frequency variation across 26 genes for a more comprehensive view of somatic variation.
This panel provides amplicon-based library preparation reagents, DNA QC, sample indexes and oligos targeting identified regions of interest. Sufficient product is supplied for 48 samples. It is supported on the MiniSeq, MiSeq, NextSeq, and HiSeq sequencing systems.
You may also be interested in our latest tumor profiling panel, TruSight Tumor 15.
For Research Use Only. Not for use in diagnostic procedures.
Kenneth Bloom, MD, FCAP, Chief Medical Officer at Clarient (GE Healthcare), discusses the practical aspects of how next-generation sequencing will be applied in the clinical laboratory.
Watch the video »
AMP2013: A multi-institutional study: Evaluation of a novel technique that uses strand-specific information to increase accuracy in a next-generation sequencing assay to identify somatic DNA variants (PDF)
Note regarding biomarker patents and other patents unique to specific uses of products:
Some genomic variants, including some nucleic acid sequences, and their use in specific applications may be protected by patents. Customers are advised to determine whether they are required to obtain licenses from the party that owns or controls such patents in order to use the product in customer's specific application.
Catalog IDs: FC-130-2001, TG-130-2001